INTRODUCTION {#s1}
============

Synthetic lethality describes the genetic interaction by which the combination of two separately non-lethal mutations results in lethality. The phenomenon was first described by Calvin Bridges in 1922 \[[@R1]\], who noticed that some combinations of mutations in the model organism *Drosophila melanogaster* confer lethality. Generally, the ablation of two genes located in parallel pathways (leading to cell survival or a common essential product) is one of the important patterns causing synthetic lethality (SL) \[[@R2]\].

Cancer is fundamentally a genetic disease with numerous gene mutations involved. Some of these genetic mutations serve as biomarkers in cancers. In particular, notable advances have been made in cancer therapy for example, with the discovery of Herceptin to treat breast cancer patients with HER2 amplification, and with Iressa for the treatment of non-small cell lung cancer patients with an EGFR mutation. However, developing drugs that selectively kill cancer cells without harming normal cells remains a big challenge in oncology therapy. Given that genetic mutations underpin differences between cancer cells and healthy cells, Hartwell \[[@R3]\] was the first to suggest the use of chemical and genetic synthetic lethality screening for cancer therapy. Since then, this approach has attracted great attention from cancer biologists as it provides a promising perspective for oncology medicine discovery \[[@R4], [@R5]\]. For example, targeting the PARP-1 enzyme using Olaparib in ovarian cancer patients carrying a tumor BRCA1/2 mutation achieved milestone success in this area \[[@R6]\]. Ultimately, siRNA and CRISPR screenings are the most reliable methods for detecting SL gene pairs. However, compared to model genetic systems (such as yeast or fruit flies), human cell systems hold greater challenges for genome-wide siRNA or CRISPR screening. For this reason, several computational approaches have been proposed to facilitate the systematic detection of SL gene pairs in cancer. Briefly, these methods can be divided into three categories according to their targeted data resources: (i) inferring human ortholog gene pairs from yeast SL genes \[[@R7]\]; (ii) using the robustness features to evaluate the importance of gene pairs in the cancer PPI network \[[@R8]\]; (iii) calculating mutual exclusivity using statistical models from gene mutation/transcriptional expression data \[[@R9]--[@R12]\]. More recently, Livnat et al. \[[@R13]\] proposed *DAISY* to identify SL gene pairs. This approach combines somatic copy number alteration, siRNA screening as well as cell survival and gene co-expression information. Derived from comprehensive in-house data, this approach achieved a promising performance in data-driving SL gene pair identification. Nevertheless, we comprehensively compared the four available predicted SL data sets from previously developed methods (including *DAISY*) \[[@R8], [@R10], [@R12], [@R13]\] on SL gene pair prediction. The concordance of predicted SL gene pairs among those different methods is extremely low (see details in *Discussions*). This inconsistency across different methods may indicate that the *in silico* SL gene pair identification methods are far from mature. In addition, none of the previous methods was learning-based, that is, SL gene pair identification was based on the screening of certain criteria rather than training and prediction. We noticed that a portion of known SL gene pairs have been accumulated, and the investigation of the characteristics of these SL gene pairs are expected to derive significant features which can quantitatively depict the common mechanisms of the SL. Therefore, in our study, we designed a learning-based pipeline to rank novel SL gene pairs based on the known SL gene pairs, together with other unknown ones. By mining the accumulated *TCGA* mutation and gene expression data, as well as the gene properties in the protein-protein interaction network, our pipeline can be treated as an integration of the traditional strategies, and ranked a list of potential SL gene pairs. In contrast to the lack of experimental validation in most previous methods, we implemented further siRNA knock-down experiments to evaluate our results.

RESULTS {#s2}
=======

Brief results of 10 times 5-fold cross validation {#s2_1}
-------------------------------------------------

We evaluated the ranking performance in 11 cancers through 10 times 5-fold cross validation, the other cancers in TCGA failed due to the limited number of overlapping samples between mutation data and the expression data or limited coverage of positive SL pairs. The brief results were listed in Table [1](#T1){ref-type="table"}. Herein we didn\'t intend to describe the details of each pair, Kidney renal clear cell carcinoma (KIRC) would be picked out as an example for illustration (see details in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Currently, TCGA mutation data contains 417 KIRC patients. In addition, the gene-expression data on 400 KIRC patients is available in the TCGA dataset. At first, 528 genes with mutation rate \>= 1% were selected from the gene mutation data. Following the workflow described in *methods*, 1014 candidate SL gene pairs were generated with the chi-square test *p* value \<=0.05 and mutation exclusivity ≥0.8. Three features (Gene pair mutation coverage, Driver mutation probability, Network information centrality) were subsequently calculated. The same calculation process was used on the 119 positive SL gene pairs covered by KIRC mutation and expression data and the cancer network. During the 10 times 5-fold cross validation procedure, the test set contained 23 or 24 SL pairs. Then the top 25 results were used for NDCG calculation and enrichment evaluation, respectively. *alpha* optimization is a critical process in data manifolds ranking algorithm, which can directly influence the ranking performance. As it was shown in Figure [1](#F1){ref-type="fig"}, NDCG\@25 was gradually increased from 0 to 0.9768, as the increase of *alpha*; while the enrichment *p* value was decreased. This means that the ranking performance was better at a larger *alpha*. Finally, the optimized *alpha* = 0.84 was achieved when NDCG\@25 reached the peak value. Then, after all of the positive SL pairs were imported as the training set with the optimized *alpha*, we generated a ranking list for the 1014 candidate pairs according to their relevance to positive pairs. The same process was implemented on 10 other cancer types. Finally, we generated a SL network in Figure [2](#F2){ref-type="fig"}, which is comprised of 107 predicted SL gene pairs from the top 10 results in the 11 cancer types. (See all of the ranking results in [Supplementary Table S2](#SD1){ref-type="supplementary-material"})

###### Ranking performance in 11 cancer types

  Cancer Type   Candidate pair Num.   Positive pair Num.   NDCG\@Positive pair/5   Enriched p value   Optimized alpha
  ------------- --------------------- -------------------- ----------------------- ------------------ -----------------
  LGG           1192                  76                   0.9808                  5.96E-13           0.56
  KIRC          1014                  119                  0.9768                  3.90E-13           0.84
  CESC          93                    38                   0.9343                  0.0027             0.98
  OV            126                   99                   0.5574                  1.50E-07           0.86
  BRCA          534                   148                  0.4618                  0.0099             0.99
  GBM           791                   49                   0.3417                  0.0262             0.99
  LUAD          766                   164                  0.3244                  0.0609             0.99
  LUSC          2177                  101                  0.2928                  5.29E-03           0.99
  SKCM          7290                  135                  0.2707                  6.24E-04           0.98
  HNSC          2213                  140                  0.2643                  0.0271             0.87
  STAD          1417                  135                  0.2372                  0.0160             0.98

![Ranking performance according to alpha\
The *X*-axis indicates the parameter alpha in manifold ranking algorithm. The *Y*-axis represents the corresponding enriched *p* value and *NDCG* in the top 25 ranking results.](oncotarget-07-55352-g001){#F1}

![SL network of the predicted 107 pairs\
Each node represents a gene. The SL relationship of a gene pair was linked by an edge. The graph was generated by *Cytoscape*.](oncotarget-07-55352-g002){#F2}

Function analysis of the genes in the predicted novel SL pairs {#s2_2}
--------------------------------------------------------------

Pathway enrichment was utilized to decipher the biological functions of the gene list. Specifically, 73/107 genes were mapped to *KEGG* pathways. From Table [2](#T2){ref-type="table"}, we can see that these genes are mainly enriched in 15 pathways (covering 61.64% of the mapped genes) involved in six biological process categories, namely, replication and repair, signal transduction, the endocrine system, cell growth and death, cellular immunity and development. In particular, the Fanconi Anemia pathway ranked No.1 as a potential pathway for identifying novel anticancer therapies by exploiting synthetic lethal relationships \[[@R14]\]. The most famous example of this is the synthetic lethality relationship between the BRCA1/2 gene in the Fanconi Anemia pathways and PARP \[[@R15]\]. Recently, the first-in-class PARP inhibitor, Olaparib, was approved by the U.S. FDA for use in advanced ovarian cancer patients with BRCA mutations \[[@R16]\]. Based on our findings, several other biological pathways for synthetic lethality exploration were identified. For example, the HIF-1 signalling pathway (which activates the transcription of genes involved in angiogenesis, cell survival, glucose metabolism and invasion), was used as a screening resource in discovering synthetic lethal gene pairs \[[@R17]\]. RAS signalling \[[@R18]\], P53 signalling \[[@R19]\], PI3K-AKT signalling \[[@R20]\], are also widely considered to be promising pathways for synthetic lethal pair identification, and have previously attracted considerable research interest.

###### Enriched pathways of the top 10 results in 11 cancer types

  Pathway Category         Pathway                             Predicted SL genes in the pathway                                                     Number of the predicted SL genes   p value
  ------------------------ ----------------------------------- ------------------------------------------------------------------------------------- ---------------------------------- ----------
  Replication and repair   Fanconi anemia pathway              ERCC1; PMS2; USP1; PALB2; ATR; FANCD2; BRCA2; ERCC4; MLH1; POLI                       10                                 3.06E-08
  Signal transduction      FoxO signaling pathway              ATM; TGFBR1; PIK3CA; PTEN; INSR; CREBBP; EP300; SMAD3; GRB2; EGFR; MAPK1; CSNK1E      12                                 7.02E-07
  Signal transduction      HIF-1 signaling pathway             VHL; PIK3CA; INSR; CREBBP; MTOR; EP300; EGFR; TLR4; PRKCA; MAPK1                      10                                 8.57E-06
  Endocrine system         Thyroid hormone signaling pathway   TP53; PIK3CA; CREBBP; MTOR; EP300; NOTCH4; ESR1; PLCE1; PRKCA; MAPK1                  10                                 1.55E-05
  Cell growth and death    Cell cycle                          TP53; ATM; CDK1; PRKDC; CREBBP; CHEK2; EP300; ATR; SMAD3; SMC1A                       10                                 2.68E-05
  Cellular community       Adherens junction                   TGFBR1; INSR; CREBBP; EP300; SMAD3; EGFR; CSNK2A1; MAPK1                              8                                  3.60E-05
  Signal transduction      Ras signaling pathway               PDGFRA; PIK3CA; INSR; PTPN11; GRB2; EGFR; NF1; KDR; PLCE1; PRKCA; MAPK1               11                                 0.00039
  Cellular community       Focal adhesion                      PDGFRA; PIK3CA; PTEN; COL1A1; MYLK; GRB2; EGFR; KDR; PRKCA; MAPK1                     10                                 0.00067
  Signal transduction      ErbB signaling pathway              PIK3CA; ERBB3; MTOR; GRB2; EGFR; PRKCA; MAPK1                                         7                                  0.00071
  Signal transduction      PI3K-AKT signaling pathway          PDGFRA; TP53; PIK3CA; PTEN; COL1A1; INSR; MTOR; GRB2; EGFR; KDR; TLR4; PRKCA; MAPK1   13                                 0.00087
  Cell growth and death    p53 signaling pathway               TP53; ATM; CDK1; PTEN; CHEK2; ATR                                                     6                                  0.0016
  Replication and repair   Nucleotide excision repair          ERCC1; ERCC5; ERCC4; RFC4; ERCC6                                                      5                                  0.0031
  Development              Dorso-ventral axis formation        GRB2; EGFR; NOTCH4; MAPK1                                                             4                                  0.0041
  Cellular community       Gap junction                        PDGFRA; CDK1; GRB2; EGFR; PRKCA; MAPK1                                                6                                  0.0049
  Signal transduction      Wnt signaling pathway               TP53; CREBBP; EP300; SMAD3; CSNK2A1; PRKCA; CSNK1E                                    7                                  0.0098

*In-vitro* drug sensitivity of cell lines in which one of the genes in each synthetic lethality pair is targeted {#s2_3}
----------------------------------------------------------------------------------------------------------------

In the process of validating the SL gene pairs in the cell lines, two strict criteria are applied in the cell response information for each SL gene pair: 1. One of the genes in a SL pair should be the target of a drug in the database. 2. Several cancer cell lines treated by the drug must possess the mutation of the other gene in the SL pair. Finally, only 37 predicted SL gene pairs could be well annotated by the drug sensitivity data in *CCLE* \[[@R21]\] and *NCI60* \[[@R22]\] databases (see Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}). We compared the drug sensitivity of the two types of cancer cell lines, namely, the cell lines with the other gene mutation and the cell lines without the other gene mutation in the SL pair. We found 4 pairs: mTOR-TP53, VEGFR2-TP53, EGFR-TP53, ATM-PRKCA which showed significantly higher drug sensitivity (targeting one of the genes in the SL pairs) in the cell lines with the other gene mutations (*P* value \<= 0.05), than the cell lines without the other gene mutation in these predicted SL pairs.

###### Comparison of drug sensitivity between two groups of cell lines in CCLE data

  Pair(Entrz Gene ID)   Gene A   Gene B     Drug targeted on gene A   Mean of drug sensitivity (PIC50)[^§^](#tfn_001){ref-type="table-fn"}   *p* value   
  --------------------- -------- ---------- ------------------------- ---------------------------------------------------------------------- ----------- ------------
  1009_7157             TP53     CDH11      Nutlin-3                  5.0978                                                                 5.1246      0.7689
  11200_4763            CHEK2    NF1        AZD7762                   6.1902                                                                 6.0711      0.1553
  11200_5290            PIK3CA   CHEK2      GDC0941                   5.1880                                                                 5.1031      0.3676
                        PIK3CA   CHEK2      NVP-BEZ235                6.9181                                                                 6.9876      0.6393
                        CHEK2    PIK3CA     AZD7762                   5.8728                                                                 6.1251      0.9818
  1387_7157             TP53     RSTS       Nutlin-3                  5.1032                                                                 5.1261      0.8182
  1956_1454             EGFR     CSNK1E     Gefitinib                 5.1213                                                                 4.9910      0.2948
                        EGFR     CSNK1E     Lapatinib                 5.1555                                                                 5.0623      0.3428
                        EGFR     CSNK1E     BIBW2992                  5.1208                                                                 5.0253      0.3775
                        EGFR     CSNK1E     Erlotinib                 5.0803                                                                 5.0415      0.4258
                        EGFR     CSNK1E     ZD-6474                   5.1210                                                                 5.2915      0.8464
  1956_7157             EGFR     TP53       BIBW2992                  5.1074                                                                 4.8862      **0.0047**
                        EGFR     TP53       Gefitinib                 5.0485                                                                 4.8969      **0.0121**
                        EGFR     TP53       ZD-6474                   5.3078                                                                 5.2584      0.0679
                        EGFR     TP53       Erlotinib                 5.0587                                                                 5.0137      0.1822
                        EGFR     TP53       Lapatinib                 5.0810                                                                 5.0339      0.1933
                        TP53     EGFR       Nutlin-3                  5.1081                                                                 5.1247      0.7205
  2065_7157             TP53     LCCS2      Nutlin-3                  5.1057                                                                 5.1251      0.7572
  2475_51366            MTOR     UBR5       Temsirolimus              6.4909                                                                 6.4765      0.4590
  2475_7157             TP53     MTOR       Nutlin-3                  5.1135                                                                 5.1240      0.6411
                        MTOR     TP53       Temsirolimus              6.4561                                                                 6.5175      0.7357
  3643_7157             TP53     INSR       Nutlin-3                  5.1204                                                                 5.1232      0.5272
  367_7157              TP53     SBMA       Nutlin-3                  5.0970                                                                 5.1248      0.7850
  3791_7157             TP53     VEGFR2     Nutlin-3                  5.1186                                                                 5.1234      0.5590
                        VEGFR2   TP53       Sorafenib                 5.0474                                                                 5.1525      0.9738
  4297_7157             TP53     MLL        Nutlin-3                  5.1239                                                                 5.1230      0.4885
  4638_7157             TP53     MYLK       Nutlin-3                  5.1091                                                                 5.1320      0.9036
  472_2885              ATM      GRB2       KU-55933                  3.6089                                                                 3.8219      0.8999
  472_3426              ATM      CFI        KU-55933                  3.7372                                                                 3.8174      0.6780
  472_5290              PIK3CA   ATM        GDC0941                   5.1010                                                                 5.1066      0.5171
                        ATM      PIK3CA     KU-55933                  3.7713                                                                 3.8224      0.7299
                        PIK3CA   ATM        NVP-BEZ235                6.9180                                                                 6.9958      0.7795
  472_5578              ATM      PRKCA      KU-55933                  3.9089                                                                 3.7880      **0.0423**
  472_5728              ATM      PTEN       KU-55933                  3.8008                                                                 3.8179      0.5858
  472_5781              ATM      PTPN11     KU-55933                  3.6390                                                                 3.8214      0.8728
  4763_7157             TP53     NF1        Nutlin-3                  5.1033                                                                 5.1260      0.8145
  4855_7157             TP53     NOTCH4     Nutlin-3                  5.1386                                                                 5.1184      0.1609
  546_5156              PDGFRA   RAD54      Pazopanib                 3.8402                                                                 4.1592      0.9844
                        PDGFRA   RAD54      Sorafenib                 4.9588                                                                 5.1008      0.9495
  5727_7157             TP53     PTCH1      Nutlin-3                  5.1016                                                                 5.1248      0.7610
  64324_7157            TP53     STO        Nutlin-3                  5.1031                                                                 5.1244      0.7307
  2475_675              MTOR     BRCA2      Temsirolimus              6.3225                                                                 6.4942      0.8553
  7099_7157             TP53     TLR4       Nutlin-3                  5.1121                                                                 5.1236      0.6151
  7157_1457             TP53     CSNK2A1    Nutlin-3                  5.0969                                                                 5.1236      0.6783
  7157_2033             TP53     EP300      Nutlin-3                  5.1252                                                                 5.1219      0.4262
  7157_2099             TP53     ESR1       Nutlin-3                  5.0986                                                                 5.1238      0.6970
  7157_4088             TP53     SMAD3      Nutlin-3                  5.1190                                                                 5.1231      0.5239
  7157_5594             TP53     PRKM2      Nutlin-3                  5.0969                                                                 5.1233      0.6144
  7157_7046             TP53     TGFBR1     Nutlin-3                  5.0969                                                                 5.1240      0.7224
  7157_983              TP53     CDK1       Nutlin-3                  5.0969                                                                 5.1233      0.6276
                        CDK1     TP53       RO-3306                   4.0215                                                                 4.0474      0.6447
  8476_7157             TP53     CDC42BPA   Nutlin-3                  5.1285                                                                 5.1226      0.4244
  9113_7157             TP53     LATS1      Nutlin-3                  5.0969                                                                 5.1247      0.7767

PIC50 means negative log~10~(IC50) values (higher value indicate higher drug sensitivity)

###### Comparison of drug sensitivity between two groups of cell lines in NCI60 data

  Pair (Entrz Gene ID)   GeneA    Gene B   Drug targeted on gene A                  Mean of drug sensitivity (z-score normalized GI50 values)[\*](#tfn_002){ref-type="table-fn"}   *p* value   
  ---------------------- -------- -------- ---------------------------------------- ---------------------------------------------------------------------------------------------- ----------- ------------
  1956_7157              EGFR     TP53     Lapatinib                                −0.1547                                                                                        0.2300      0.0791
                         EGFR     TP53     Erlotinib hydrochloride                  −0.0997                                                                                        0.0925      0.2517
                         EGFR     TP53     Gefitinib                                −0.0414                                                                                        0.1119      0.2968
                         EGFR     TP53     Afatinib                                 −0.0551                                                                                        −0.0219     0.4541
  2475_7157              MTOR     TP53     Sirolimus                                −0.2149                                                                                        0.3950      **0.0070**
                         MTOR     TP53     Temsirolimus                             −0.1846                                                                                        0.4443      **0.0146**
                         MTOR     TP53     Everolimus                               −0.1158                                                                                        0.2619      0.0771
  367_7157               SBMA     TP53     Dromostanolone Propionate                −0.1572                                                                                        0.2575      0.0519
                         SBMA     TP53     Calusterone                              −0.0156                                                                                        0.1200      0.3373
                         SBMA     TP53     Nandrolone phenpropionate                0.0200                                                                                         −0.0169     0.5508
  3791_7157              VEGFR2   TP53     Pazopanib hydrochloride                  −0.2302                                                                                        0.4594      **0.0052**
                         VEGFR2   TP53     Axitinib                                 −0.1028                                                                                        0.2731      0.1062
                         VEGFR2   TP53     Sunitinib malate/Sunitinib (free base)   −0.0886                                                                                        0.17125     0.1696
  7157_2099              ESR1     TP53     Raloxifene hydrochloride                 −0.1808                                                                                        0.2231      0.0740
                         ESR1     TP53     Fulvestrant                              −0.1194                                                                                        0.2606      0.1093
                         ESR1     TP53     Tamoxifen citrate                        −0.0158                                                                                        0.0525      0.3947
                         ESR1     TP53     Estramustine phosphate sodium            −0.1011                                                                                        −0.0450     0.4061
  7157_5594              PRKM2    TP53     Arsenic Trioxide                         −0.0272                                                                                        0.0275      0.4218

z score normalized GI50 values are the elements of cellular fingerprint in NCI60 dataset. (<http://data-analysis.charite.de/care/index.php?site=about#usecase>) (Smaller values indicate higher drug sensitivity)

Possible molecular mechanisms of the 4 positive pairs {#s2_4}
-----------------------------------------------------

According to Kaelin \[[@R23]\]\'s synthetic lethality model, synthetic lethality occurs via 4 different mechanisms: The cellular organizational units may be uniquely redundant and their roles are essential (type A), subunits of an essential multi-protein complex (type B), interconnected components in an essential linear pathway (type C), or they may participate in parallel pathways that are together essential (type D). The 4 pairs were consistent with either type D or type C.

mTOR-TP53 {#s2_5}
---------

mTOR can integrate nutrient and mitogen signals to activate cell growth (increase cell mass and cell size) and cell division \[[@R24], [@R25]\], whilst one of the most important functions of TP53 is its ability to activate apoptosis \[[@R26]\]. Cell growth and apoptosis may provide parallel functions in cancer pathology. mTOR and TP53 may be considered synthetic lethality targets.

VEGFR2-TP53, EGFR-TP53 {#s2_6}
----------------------

EGFR is a hot target for cancer therapy with many currently FDA approved drugs, and can activate at least 4 major downstream signalling cascades including; RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. Those signalling cascades can ultimately lead to a series of cellular events such as cell proliferation, inhibition of apoptosis, angiogenesis, migration, adhesion and invasion \[[@R27]\]. Furthermore, VEGF\'s can specifically induce blood and lymphatic vessel development and homeostasis \[[@R28]\]. Inhibition of EGFR can block the angiogenesis process. Double knock out VEGFR2 and TP53 may lead to synthetic lethality through angiogenesis and apoptosis.

ATM-PRKCA {#s2_7}
---------

ATM \[[@R29]\] is a key regulator of multiple signaling cascades that respond to DNA damage. These responses involve the activation of cell cycle checkpoint factors, DNA repair and apoptosis. PRKCA has long been recognized to participate in activating tumour growth and development across different cancers \[[@R30]\]. In addition, PRKCA activation can result in increased cell motility in several *in vivo* and *in vitro* cancer models, the effect of which may be reversed with PRKCA inhibition \[[@R31], [@R32]\]. Hence, ATM and PRKCA knock-out, coupled with loss of function of apoptosis and the cell migration process, may generate synthetic lethality.

Validation through siRNA knock-down in cancer cell lines {#s2_8}
--------------------------------------------------------

Regarding the mutation information in the *CancerDR* database \[[@R33]\], three cancer cell lines were selected (Table [5](#T5){ref-type="table"}). MCF-7 is a breast cancer cell line, carrying wild type TP53 and PRKCA. FaDu is a human epithelial cell line with mutant TP53 and SW48 is an invasive human colon adenocarcinoma cell line with a PRKCA mutation. Since an extremely low level of VEGFR2 mRNA expression was detected in the FaDu line, only three gene pairs (TP53-mTOR, TP53-EGFR, PRKCA-ATM) were able to be analyzed for siRNA knock-down validation. The relative cell growth results are displayed in Figure [3](#F3){ref-type="fig"}.

###### siRNA knock-down on the cancer cell lines

  SL pair (Entrz Gene ID)   Gene A   Cell line with wild type gene A   Cell line with mutant gene A   siRNA knock down gene B
  ------------------------- -------- --------------------------------- ------------------------------ -------------------------
  7157-2475                 TP53     MCF-7                             FaDu                           MTOR
  7157-1956                 TP53     MCF-7                             FaDu                           EGFR
  7157-3791                 TP53     MCF-7                             FaDu                           VEGFR2
  472-5578                  PRKCA    MCF-7                             SW48                           ATM

![The relative cell growth of cancer cell lines\
**A.** The relative cell growth of MCF7 and FaDu with siRNA knock-down of mTOR. **B.** The relative cell growth of MCF7 and FaDu with siRNA knock-down of EGFR. **C.** The relative cell growth of MCF7 and SW48 with siRNA knock-down of ATM.](oncotarget-07-55352-g003){#F3}

siRNA knock-down validation on TP53-mTOR {#s2_9}
----------------------------------------

According to the results of mRNA expression detection, there was no significant difference in the mTOR knock-down rate between MCF7 and FaDu (average mTOR knock-down rate: MCF7 62.26%; FaDu 60.67%). As shown in Figure [3A](#F3){ref-type="fig"}, the cell growth inhibitory effect of mTOR knock-down was observed in both MCF7 and FaDu. 96 hours after mTOR siRNA knock-down, the relative cell growth of FaDu slightly decreased from 1.1596 to 0.8178, while the relative cell growth of MCF7 dramatically decreased from 0.9509 to 0.4581. 24 hours after mTOR knock-down, the relative cell growth of MCF7 was always significantly lower than FaDu with a t-test *P* value of less than 0.01. The lowest inhibition of cell growth (54.19%) was achieved after 96 hours of mTOR knockdown in the MCF7 cells. This may indicate that wild type TP53 in the MCF7 line can possibly strongly enhance the cell growth inhibition effects of mTOR knock-down, compared to the mutant TP53 in FaDu.

siRNA knock-down validation on TP53-EGFR {#s2_10}
----------------------------------------

Also, no significant difference in the EGFR siRNA knock-down rate was detected between MCF7 and FaDu. The optimal knock-down rates were 82.81% and 88.87% in FaDu and MCF7, respectively. Figure [3B](#F3){ref-type="fig"} displays the relative cell growth of MCF7 and FaDu cells after EGFR siRNA knock-down within 96 hours. No inhibition of cell growth using EGFR knock-down was observed in FaDu cells. The average relative cell growth was maintained at around 0.9325 \~ 1.0300 upon EGFR knock-down, whilst the relative cell growth of MCF7 strongly decreased from 0.9595 to 0.6884 following EGFR knock-down. 24 hours after EGFR knock-down, the relative cell growth of the MCF7 line was always significantly lower than the FaDu line with a t-test *P* value of less than 0.01. The wild type TP53 in MCF7 cells with EGFR knock-down could lead to cell growth inhibition.

siRNA knock-down validation on PRKCA-ATM {#s2_11}
----------------------------------------

Upon siRNA transfection, the average knock-down rates of ATM were 86.07% and 45.43% in MCF7 and SW48 cells, respectively. Figure [3C](#F3){ref-type="fig"} shows the relative cell growth of MCF7 and SW48 cells with ATM siRNA knock-down. The relative cell growth of MCF cells decreased slightly from 1.030 to 0.9208. Considering the high ATM siRNA knock-down efficiency, this suggests that ATM knock-down has very limited inhibition effects on MCF cell growth. For SW48 cells, the relative cell growth decreased from 0.9936 to 0.8495. 96 hours after ATM knock-down, the relative cell growth of SW48 was significantly lower than MCF7 (0.8495 ± 0.0209 vs. 0.9208 ±0.0636, t test *P* value = 0.01296). This may partly indicate that the mutant PRKCA in SW48 cells can enhance the inhibition of cell growth on ATM knock-down, compared to the wild type PRKCA in MCF7. The slight inhibition observed on SW48 cell growth may be caused by the low ATM siRNA knock-down rate in the cell. It may be a novel SL gene pair with further rigorous validation.

DISCUSSION {#s3}
==========

Regarding the predicted SL gene pairs: mTOR-TP53 and EGFR-TP53, we found that mTOR knock-down or EGFR knock-down could cause much stronger cell growth inhibition in cell lines with wild type TP53, compared to mutant TP53. It seems that the relationships between mTOR-TP53 and EGFR-TP53 are exactly opposed to the concept of synthetic lethality. Indeed, the multifunctional nature of mutant TP53 needs to be better understood. A series of earlier studies \[[@R34]--[@R37]\] had suggested that mutant TP53 not only represents the equivalent of wild type TP53 functional loss, but also acquires new functions in driving cell migration, invasion and metastasis. The significant differences in cell growth between cancer cell lines with wild type TP53 and mutant TP53 could partly suggest that there is a special relationship between TP53-mTOR and TP53-EGFR. Notably, TP53 may be a promising biomarker in the development of cancer drugs targeting the mTOR and EGFR pathways in precision medicine.

siRNA knock-down is limited by both the expression level of the gene in the cell and the knock-down efficiency of the siRNA. In our study, we failed to validate VEGFR2-TP53 due to the low expression levels of VEGFR2 in the FaDu cell line. The low knock-down rate (45%) of ATM may weaken the inhibitory effects on cell growth. In response to these issues, the latest CRISPR technology \[[@R38], [@R39]\], which can provide considerable gene editing power, may provide a more reliable approach to further validate SL gene pairs.

Detecting SL gene pairs in humans is a challenging problem due to the highly evolved, complex and redundant signalling pathways within human cells. The influence of a loss of function caused by gene mutation can often be complemented by parallel pathway signalling. Various computational methods can provide potential SL gene pairs from different perspectives, such as the correlation of gene expression with mutation, robustness in the cancer network or gene co-expression in related biological processes. In this study, we compared the 107 predicted SL pairs with the results of four previous methods (see details in [Supplementary Table S3](#SD1){ref-type="supplementary-material"}). As shown in Figure [4](#F4){ref-type="fig"}, 12.15% (13 pairs) of our predicted results overlapped with Wang\'s \[[@R10]\] or Kranthi\'s \[[@R8]\] prediction. Importantly, TP53-mTOR and EGFR-TP53 pairs validated by drug sensitivity data were included in the overlapping pairs. This may suggest that overlapping predictions from different methods may provide more reliable results. Interestingly, we also found that no overlap occurred between Livnat\'s \[[@R13]\] predictions or any of the other four methods. The original input data may be one of the important factors in influencing the final predictions. Kranthi\'s method \[[@R8]\] started with the human protein-protein interaction database HPRD \[[@R40]\] as well as CancerGenes \[[@R22]\]. Wang\'s prediction \[[@R10]\] was based on the profiling data of glioblastoma multiforme from *TCGA* as well as the p53 mutation information from the *Trust Sanger Institute*. Srihari \[[@R12]\] used the copy-number and gene-expression profiling data of four cancers (breast, prostate, ovarian and uterine) in *TCGA* as input data for their method. The different features of these input data across the methods may generate bias in SL gene pair predictions. Since there was no *priori* knowledge of cancer targets in the NCI-60 database, *CancerGenes* or *Metacore* were used to filter the input data in Livnat\'s model \[[@R13]\], the potential SL gene pairs from the cancer lines may lead to distinct prediction results from others. In addition, due to the low concordance of results between different methods, further efforts to explore such complex SL relationships in a human system may be required.

![Comparison of the predicted results with other methods\
The Venn diagram was drawn based on the overlap of the predicted SL gene pairs in three previous reports and our results.](oncotarget-07-55352-g004){#F4}

CONCLUSIONS {#s4}
===========

In this study, we proposed a semi-supervised ranking pipeline to rank novel SL gene pairs based on the vast amounts of accumulated *TCGA* data. 107 novel potential SL gene pairs were predicted from the top 10 results covering 11 cancers. In particular, 4 SL pairs: mTOR-TP53, VEGFR2-TP53, EGFR-TP53, ATM-PRKCA, could be validated using drug sensitivity information in the cancer cell line databases *CCLE* or *NCI60*. Furthermore, the results of siRNA knock-down experiments indicated that significant differences in the cell growth of mTOR or EGFR siRNA knock-down were detected between the cancer cells with wild type TP53 and mutant TP53. The TP53 mutation may serve as a biomarker for cancer therapy in drugs targeting mTOR or EGFR. More promisingly, a recent study \[[@R41]\] has proposed P53 as a biomarker for predicting the progression free survival (PFS) of pancreatic cancer patients being treated with erlotinib (EGFR inhibitor). Taken together, these data underscore the potential of investigating the role of P53 as a predictive biomarker in other cancer types.

MATERIALS AND METHODS {#s5}
=====================

SL gene pair prediction pipeline {#s5_1}
--------------------------------

In this study, we designed a semi-supervised learning model \[[@R42]\] to rank the similarities between positive SL gene pairs and candidate SL gene pairs, mainly using 3 defined features namely, gene pair mutation coverage, driver mutation probability and the quantified network information centrality. More specifically, we used three features to describe both the known SL gene pairs and candidate SL gene pairs. Then the semi-supervised method could rank the candidate SL gene pairs according to the similarity of these features with the known SL gene pairs. Herein, gene pair mutation coverage was defined as the percentage of samples containing at least one gene mutation in the pair. Furthermore, in order to get more reliable results from TCGA mutation data, the mutations of genes in candidate SL pairs should be covered by a certain number of samples. Driver mutations play vital roles in cancer development. Regarding the cancer specific SL pairs, we hypothesised that the mutation of genes playing an important role in cancer progression are more likely to be driver mutations. Last, the network information centrality helps to identify the potential nodes, which are crucial for the proper functioning of the system. Since simultaneously mutating two genes in a SL gene pair could dramatically influence the cellular process and cause cell death, network information centrality was used to calculate the influence of knocking-out a node pair on system stability. This approach inherently mimics the synthetic lethality mechanism well.

The brief workflow of the SL prediction pipeline is shown in Figure [5](#F5){ref-type="fig"}. In the first step, cancer biomarkers were collected from *COSMIC* \[[@R43]\] and *MetaCore* \[[@R44]\], which were used as a filter to select raw cancer related SL pairs. Next, the positive SL pairs were generated from yeast SL pairs, followed by homolog gene transformation, cancer biomarker filtering as well as the application of evidence in human cell lines obtained from literature mining. The candidate genes were selected from *TCGA* mutation data. The raw candidate SL pairs were then composed based on a candidate gene and a gene within a cancer network. Then, a Chi-square test (implemented by *chi2_contingency* in python package *Scipy*) was used to evaluate whether the mutations of the two genes is an independent event in each raw candidate SL pair. In addition, the mutation exclusivity was also calculated, which was defined as the percentage of samples carrying one of the mutant genes in the SL gene pair \[[@R9]\]. Only those independent gene mutations with high mutation exclusivity were selected as candidate SL pairs for further calculation. Subsequently, three features of both candidate SL pairs and positive SL pairs were calculated and normalized before being exported into a learning model. Finally, the novel SL pairs were detected with an optimized parameter which was obtained from 10 times 5-fold cross validation.

![Workflow of the SL prediction pipeline\
The three types of original data (gene mutation and expression, cancer biomarker, SL-pairs in yeast) were downloaded from *TCGA*, *COSMIC* and *MetaCore* as well as *BIOGRID*, respectively. The cancer network was built from the interaction of cancer biomarkers in the protein-protein interaction database *HPRD*. Each raw candidate SL pair was composed of a highly mutated gene and another gene in the cancer network. Then a chi-square test on the mutation exclusivity with *p* value \<= 0.05 was utilized to generate the candidate SL pairs, while the positive SL pairs were derived from the yeasts' SL pairs followed by homology transformation, cancer biomarker filtration and literature evidence identification on human cell lines. For each pair in of candidate SL and positive SL data, three features were generated for them. The first feature was calculated from the mutation coverage of each SL gene pair in the *TCGA* mutation data. The driver mutation probability was calculated by *R* package *DriverNet*. The third feature was defined to evaluate the influence on stability of the cancer network, after removing the two genes from an SL pair. Then normalized features of each SL pair were imported into a manifolds ranking model to generate a ranking list of potential SL pairs.](oncotarget-07-55352-g005){#F5}

*TCGA* mutation and expression data processing {#s5_2}
----------------------------------------------

We downloaded *TCGA* mutation and expression profiling data from the UCSC Cancer Genomics Browser ([https://genome-cancer.ucsc.edu](https://genome-cancer.ucsc.edu/)), which provides well-annotated and interactive visualizations of *TCGA* genomic, phenotypic, and clinical data \[[@R45]\]. We then obtained two matrices. Each row of the matrices represented a gene, and each column indicated a sample. The values in the cells represented the expression and mutation status in the gene expression matrix and the gene mutation matrix, respectively. Finally, data from 11 cancers, containing both the gene expression matrix and the corresponding gene mutation matrix, were used in our study.

Positive synthetic lethality gene pairs {#s5_3}
---------------------------------------

The collective data on yeast SL (synthetic lethal) genes based on high throughput genetic screening is available at *BioGRID* \[[@R46]\]. However, no curated database of human SL gene pairs has been established yet. In this study, *BioGRID* was used as the primary resource to retrieve human cancer related SL gene pairs. The phylogenetic inference from yeast to human genes was obtained from the Ensemble database (<http://useast.ensembl.org/>). Then, homolog human SL pairs were filtered by cancer biomarkers in *MetaCore* (<https://portal.genego.com/>) and driver genes in *COSMIC* \[[@R43]\]. Only homolog human SL gene pairs with both of the genes covered by cancer biomarkers or driver genes were kept for downstream analysis. In order to reduce the false positive rate as much as possible, for each homolog human SL gene pair, we checked the evidence available in the PubMed literature. Finally, 399 positive SL pairs were identified with the evidence of synthetic lethality in human cell lines or animal models in the literature (see [Supplementary Table S4](#SD1){ref-type="supplementary-material"}).

Cancer network {#s5_4}
--------------

307,066 protein-protein interactions were downloaded from *HPRD* \[[@R40]\]. Then, we used cancer biomarkers from *MetaCore* and *COSMIC* \[[@R43]\] to filter them. In details, we searched the keywords 'cancer, tumor, carcinoma' in *MetaCore* and retrieved 4,296 cancer related biomarkers. At the same time, we also downloaded the 507 driver mutation genes collected in the Cancer Gene Census from the website of *COSMIC*. All of these gene mutations in Cancer Gene Census have been proved to causally implicate in cancer. Then, for each protein-protein interaction, only if both proteins are included in *MetaCore* cancer biomarkers or Cancer Gene Census in *COSMIC*, would the protein-protein interaction be kept. Finally, we obtained 11,925 protein-protein interaction pairs, corresponding to 2,869 individual proteins. The cancer network could be built with edge presented by the protein-protein interaction, as well as the node displayed by a protein.

Candidate SL pairs generation {#s5_5}
-----------------------------

We calculated the mutation rate of each gene among the samples in the *TCGA* mutation data. Herein, 1% was utilized as the cut-off threshold to select the candidate genes. Each raw candidate SL gene pair was generated by selecting a candidate gene as well as the other gene from the cancer network. Subsequently, we tested whether *gene A* mutation and *gene B* mutation are independent events based on the mutation data. In detail, the null hypothesis is that *gene A* mutation and *gene B* mutation are independent of each other. A Chi-square test was implemented on a 2×2 contingency table (see Table [6](#T6){ref-type="table"}). *M* represents the number of samples carrying both *gene A* and *gene B* mutations; *N* represents the number of samples carrying the *gene A* mutation without the *gene B* mutation; *X* represents the number of samples carrying the *gene B* mutation without the *gene A* mutation; *Y* is the number of samples that containing both wild type *gene A* and wild type *gene B*.

###### 2×2 contingency table in chi-square test

                                                *gene B* [+](#tfn_003){ref-type="table-fn"}   *gene B* [−](#tfn_004){ref-type="table-fn"}
  --------------------------------------------- --------------------------------------------- ---------------------------------------------
  *gene A* [+](#tfn_003){ref-type="table-fn"}   *M*                                           *N*
  *gene A* [−](#tfn_004){ref-type="table-fn"}   *X*                                           *Y*

mutant type

wild type

The raw candidate SL gene pairs with Chi-square test p value \<=0.05 means the mutation of *gene A* and *gene B* are not independent. Maybe some relationships exist between mutation of *gene A* and *gene B.* In addition, the mutation exclusivity of *gene A* and *gene B* could be calculated as (X+N)/(M+N+X). The higher mutation exclusivity indicates the gene A and gene B are more likely to be mutually exclusive mutations. Herein, only candidate SL pairs with both Chi-square test P value ≤ 0.05 and mutation exclusivity ≥ 0.8 were selected for the downstream processing.

Features calculation {#s5_6}
--------------------

### Gene pair mutation coverage {#s5_6_1}

It was defined as the percentage of samples containing at least one gene mutation in the pair. For example, *gene A* is mutated in samples *s1,s3,s6, gene B* is mutated in samples *s3,s8,s9*. *n* is the total number of samples. The mutation coverage of the pair (*gene A, gene B*) is 5/*n*.

### Driver mutation probability {#s5_6_2}

Herein, we utilized the *R* package *DriverNet* \[[@R47]\] to evaluate the driver mutation probability of genes based on the relationship between mutation and consequent changes in gene expression. The input data of *DriverNet* comes from two matrices, namely a mutation matrix and its corresponding gene expression matrix. Each column of the two matrices is a sample, whilst each row represents the mutation status or expression level of a gene among the samples. The output of *DriverNet* is the *P* value of each gene that will likely be a driver of gene mutation. The smaller *P* value of the two genes from a SL pair was transformed to a negative log10 (*P* value) indicating the strength of the driver mutation for the pair.

### Network information centrality {#s5_6_3}

If *G* refers to the cancer network mentioned above, and *G'* refers to the cancer network after removing *gene A* and *gene B*, then the network information centrality of *gene A* and *gene B* could be defined as formula [I](#equ-001){ref-type="disp-formula"}: $$C_{\textit{geneA},\textit{geneB}} = \left| \frac{\Delta E}{E} \right| = \left| \frac{E\left( G \right) - E\left( G^{\prime} \right)}{E\left( G \right)} \right|$$

Where *E*(*G*) is the efficiency of the network. It could be calculated in the formula [II](#equ-002){ref-type="disp-formula"}: $$E\left( G \right) = \frac{1}{N\left( {N - 1} \right)}\Sigma_{i \neq j;i,j\text{   }G}\frac{1}{d_{\textit{ij}}}$$

Herein, if *gene i* could reach *gene j* in cancer network, *d*~*ij*~ is the length of the shortest path between the *gene i* and *gene j* (calculated by *shortest_path_length* in python package *networkx*)*,* otherwise, *d*~*ij*~ is equal to *D(G) +* 1*. D(G)* represents the diameter of cancer network, which is defined as the largest distance across all of the shortest paths in the cancer network (calculated through *diameter* in python package *networkx*).

Finally, normalization of the three features was taken to transform the values of each feature between 0-1 in formula [III](#equ-003){ref-type="disp-formula"}. *x* is the original value of a feature. *x'* is the normalized value.
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A semi-supervised ranking model {#s5_7}
-------------------------------

The principle of our ranking model, which is referred to as a manifold ranking algorithm \[[@R42], [@R48]\] can be intuitively explained: the problem is defined in two datasets, a true sample set and an unknown sample set (background); and the goal is to rank the individual members of the unknown sample set according to their *relevance* to the true samples. This model is well suited to address our problem scenario, which is that we only have few known SL pairs in hand (known positive data samples), and we want to prioritize the largest possible gene pair combinations based on their possibility to be the true SL pairs. In detail, we used three features to describe each SL pair. Then 1- cosine angle distance was calculated to represent the *relevance* between candidate SL pairs and true SL pairs.

**Input**: A set of points *X* = (*x~1~*... *x~q~*, *x~q\ +\ 1~*... *x~n~*) representing the SL pairs. The first *q* points are true SL pairs, while, the others are candidate SL pairs. The initial score *y* was defined as (1...1,0 ...0). (The true SL pairs are corresponding to 1, candidate SL pairs are assigned as 0.) Define *f^0^* = *y*; α is a parameter of the algorithm.

**Output**: A ranked list of *X*, where higher ranked gene pairs are more likely to be SL gene pairs.

1.  Define the similarity matrix *W~ij~* = 1- *cosine(i,j)* and *W~ii~* = 0.

2.  Compute *L* = *D^−1/2^WD^−1/2^* with *D* being a diagonal matrix defined as $D_{\textit{ii}} = {\sum_{j = 1}^{n}W_{\textit{ij}}}$

3.  Set iteratively *f^t+1^* = *αLf^t^* + *(1-α)y* until f converges, where α is a parameter in \[0, 1);

4.  Let *f\** be the converged function *f^t^*; and rank all the points *X* in the decreasing order of their *f*\* values.

It has been shown \[[@R42]\] that *f* \* could be calculated as formula [IV](#equ-004){ref-type="disp-formula"}.
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Evaluation test design {#s5_8}
----------------------

### 10 times 5-fold cross validation {#s5_8_1}

For each case, the positive SL pairs were divided into five segments. Four of them were used as training sets, while the rest of the segments were used for evaluation. Next, positive SL pairs were shuffled 10 times, the overall performance was determined by the average results of these 10 shuffling events.

### Ranking performance evaluation {#s5_8_2}

Normalized discounted cumulative gain (*NDCG*) \[[@R49]\] was originally used to evaluate web search engine algorithms in the field of information retrieval. It can measure the usefulness of a document based on its position in the result list. Here we used NDCG to measure the effectiveness of ranking performance for each case\'s predicted results (see formula [V](#equ-005){ref-type="disp-formula"}).
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*Z* is the normalization constant.

*i* is the rank position of candidate SL pair *m*.

*rel~i~* is the relevance value of candidate SL pair *m*. If candidate SL pair *m* belongs to the positive SL pairs, *rel~i~* is set to 1, otherwise, *rel~i~* is set to 0.

*p* is the maximum position.

For example, if the three positive SL pairs are ranked at 2, 3 & 8, respectively, while the ideal rank position should be 1, 2 & 3, then: $$Z = \frac{1}{\sum_{i = 1}^{3}\frac{1}{\log_{2}\left( {i + 1} \right)}} = 0.4331$$

In the top 5 results, $$\textit{NDCG}@5 = Z \bullet \left( {\frac{1}{\log_{2}\left( {2 + 1} \right)} + \frac{1}{\log_{2}\left( {3 + 1} \right)}} \right) = 0.4907$$

In addition, the positive enrichment of SL pairs in the top *n* ranking position are also used to evaluate our prediction performance. Herein, a hypergeometric test is utilized. (see formula [VI](#equ-008){ref-type="disp-formula"}) $$p = 1 - {\sum\limits_{x = 0}^{k}\frac{C_{M}^{x} \bullet C_{N - M}^{n - x}}{C_{N}^{n}}}$$

*k*: number of positive SL pairs included in top *n* ranking results.

*N*: the whole candidate SL pairs

*M*: the whole positive SL pairs.

Comparison of drug sensitivities between two groups of cancer cell lines {#s5_9}
------------------------------------------------------------------------

The original drug sensitivity data, drug targets as well as the mutation backgrounds of cancer cell lines in *CCLE* \[[@R21]\], *NCI60* \[[@R22]\] were downloaded from [broadinstitute.org/ccle/home](http://broadinstitute.org/ccle/home) and [discover.nci.nih.gov/cellminer/](http://discover.nci.nih.gov/cellminer/), respectively. Regarding a SL gene pair, if one of the genes in the SL pair is targeted by a drug, we compared the drug sensitivities on the cell lines carrying the mutation of the other genes in the pair and the cell lines containing the wild type of the other genes. The lower GI50 or IC50 value means higher drug sensitivity.

Further validation through siRNA knock down on cell lines {#s5_10}
---------------------------------------------------------

In order to get more reliable validation of the predicted SL gene pairs, we conducted siRNA knock-down experiments on cancer cell lines. The influence on cell growth of different genetic background cell lines would indicate SL relationships.

For example, regarding a SL gene pair *gene a* --*gene b*, two cancer cell lines were selected. The first cell line carried mutant *gene a*, while the wild type *gene a* was carried in the other cell line. Then, the siRNA of *gene b* was transfected into the two cell lines. We recorded the cell growth of two cell lines at the time points of 0h, 24h, 48h, 72h and 96h on two different treatments: placebo, siRNA-knockdown of *gene b*, respectively. Herein, we did 8 parallel experiments at each time point. The relative cell growth was calculated through the formula [VII](#equ-009){ref-type="disp-formula"}.

Relative cell growth

=

Growth of cell with siRNA treatment

Growth of cell with placebo treatment
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